Background: Optimal consolidation for young patilents with relapsed/refractory (R/R) follicular lymphoma (FL) remains uncertain in the rituximab era, with an unclear benefit of autologous stem cell transplantation (ASCT). The multicenter, randomized, phase III FLAZ12 (NCT01827605) trial compared anti-CD20 radioimmunotherapy (RIT) with ASCT as consolidation after chemoimmunotherapy, both followed by rituximab maintenance. Patients and methods: Patients (age 18-65 years) with R/R FL and without significant comorbidities were enrolled and treated with three courses of conventional, investigator-chosen chemoimmunotherapies. Those experiencing at least a partial response were randomized 1: 1 to ASCT or RIT before CD34+ collection, and all received postconsolidation rituximab maintenance. Progression-free survival (PFS) was the primary endpoint. The target sample size was 210 (105/group). Results: Between August 2012 and September 2019, of 164 screened patients, 159 were enrolled [median age 57 (interquartile range 49-62) years, 55% male, 57% stage IV, 20% bulky disease]. The study was closed prematurely because of low accrual. Data were analyzed on 8 June 2023, on an intention-to-treat basis, with a 77-month median follow-up from enrollment. Of the 141 patients (89%), 70 were randomized to ASCT and 71 to RIT. The estimated 3-year PFS in both groups was 62% (hazard ratio 1.11, 95% confidence interval 0.69-1.80, P = 0.6662). The 3-year overall survival also was similar between the two groups. Rates of grade ≥3 hematological toxicity were 94% with ASCT versus 46% with RIT (P < 0.001), and grade ≥3 neutropenia occurred in 94% versus 41%, respectively (P < 0.001). Second cancers occurred in nine patients after ASCT and three after radioimmunotherapy (P = 0.189). Conclusions: Even if prematurely discontinued, our study did not demonstrate the superiority of ASCT versus RIT. ASCT was more toxic and demanding for patients and health services. Both strategies yielded similar, favorable long-term outcomes, suggesting that consolidation programs milder than ASCT require further investigation in R/R FL.

Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial / Ladetto, M.; Tavarozzi, R.; Zanni, M.; Evangelista, A.; Ferrero, S.; Tucci, A.; Botto, B.; Bolis, S.; Volpetti, S.; Zilioli, V. R.; Puccini, B.; Arcari, A.; Pavone, V.; Gaidano, G.; Corradini, P.; Tani, M.; Cavallo, F.; Milone, G.; Ghiggi, C.; Pinto, A.; Pastore, D.; Ferreri, A. J. M.; Latte, G.; Patti, C.; Re, F.; Benedetti, F.; Luminari, S.; Pennese, E.; Bossi, E.; Boccomini, C.; Anastasia, A.; Bottelli, C.; Ciccone, G.; Vitolo, U.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 35:1(2024), pp. 118-129. [10.1016/j.annonc.2023.10.095]

Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial

Luminari S.;
2024

Abstract

Background: Optimal consolidation for young patilents with relapsed/refractory (R/R) follicular lymphoma (FL) remains uncertain in the rituximab era, with an unclear benefit of autologous stem cell transplantation (ASCT). The multicenter, randomized, phase III FLAZ12 (NCT01827605) trial compared anti-CD20 radioimmunotherapy (RIT) with ASCT as consolidation after chemoimmunotherapy, both followed by rituximab maintenance. Patients and methods: Patients (age 18-65 years) with R/R FL and without significant comorbidities were enrolled and treated with three courses of conventional, investigator-chosen chemoimmunotherapies. Those experiencing at least a partial response were randomized 1: 1 to ASCT or RIT before CD34+ collection, and all received postconsolidation rituximab maintenance. Progression-free survival (PFS) was the primary endpoint. The target sample size was 210 (105/group). Results: Between August 2012 and September 2019, of 164 screened patients, 159 were enrolled [median age 57 (interquartile range 49-62) years, 55% male, 57% stage IV, 20% bulky disease]. The study was closed prematurely because of low accrual. Data were analyzed on 8 June 2023, on an intention-to-treat basis, with a 77-month median follow-up from enrollment. Of the 141 patients (89%), 70 were randomized to ASCT and 71 to RIT. The estimated 3-year PFS in both groups was 62% (hazard ratio 1.11, 95% confidence interval 0.69-1.80, P = 0.6662). The 3-year overall survival also was similar between the two groups. Rates of grade ≥3 hematological toxicity were 94% with ASCT versus 46% with RIT (P < 0.001), and grade ≥3 neutropenia occurred in 94% versus 41%, respectively (P < 0.001). Second cancers occurred in nine patients after ASCT and three after radioimmunotherapy (P = 0.189). Conclusions: Even if prematurely discontinued, our study did not demonstrate the superiority of ASCT versus RIT. ASCT was more toxic and demanding for patients and health services. Both strategies yielded similar, favorable long-term outcomes, suggesting that consolidation programs milder than ASCT require further investigation in R/R FL.
2024
35
1
118
129
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial / Ladetto, M.; Tavarozzi, R.; Zanni, M.; Evangelista, A.; Ferrero, S.; Tucci, A.; Botto, B.; Bolis, S.; Volpetti, S.; Zilioli, V. R.; Puccini, B.; Arcari, A.; Pavone, V.; Gaidano, G.; Corradini, P.; Tani, M.; Cavallo, F.; Milone, G.; Ghiggi, C.; Pinto, A.; Pastore, D.; Ferreri, A. J. M.; Latte, G.; Patti, C.; Re, F.; Benedetti, F.; Luminari, S.; Pennese, E.; Bossi, E.; Boccomini, C.; Anastasia, A.; Bottelli, C.; Ciccone, G.; Vitolo, U.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 35:1(2024), pp. 118-129. [10.1016/j.annonc.2023.10.095]
Ladetto, M.; Tavarozzi, R.; Zanni, M.; Evangelista, A.; Ferrero, S.; Tucci, A.; Botto, B.; Bolis, S.; Volpetti, S.; Zilioli, V. R.; Puccini, B.; Arcar...espandi
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0923753423042400-main.pdf

Open access

Tipologia: VOR - Versione pubblicata dall'editore
Dimensione 516.86 kB
Formato Adobe PDF
516.86 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1367816
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact